CEO, Executive Board Member
Dr. Irvin is an active participant in many Biotechnology and Health Science endeavors and is an expert including patent generation in such areas as treatments for Parkinson’s, brain cancer, and even cosmetic application of advanced bioscience. He is also an expert in the physical operations of laboratories, and hospitals. He received his Ph.D. from UCLA School of Medicine, and Masters in Public Health from UCLA School of Public Health, and trained at The Wallenberg Neuroscience Center at Lund University in Lund, Sweden. He was also a Professor, Faculty member at Cedars-Sinai Medical Center, Department of Neurosurgery.
Dr. Irvin’s Ph.D. is in Pharmacology and Developmental Neuroscience with an emphasis on neural stem cell fate and differentiation. His research focused on neural development and Notch Signaling inmammalian neural stem cells.
He also worked as an NIH/NINDS Post-Doctoral Fellow in Dr. Anders Bjorklund laboratory in Lund, Sweden. There, his focus was on research projects that investigated the potential role of cell replacement therapy for patients with Parkinson’s disease. They developed several protocols for the efficient generation of dopaminergic neurons from forebrain and ventral midbrain stem and progenitor cells.
Additionally, Dr. Irvin led research investigations in the role of adaptive immunity in Parkinson’s disease. He also developed two patents in the area of immunotherapy for brain tumor patients, specifically Glioblastoma Multiforme (GBM). His research team focused on molecular mechanisms that impart therapeutic resistance in cancer cells, including cancer stem cells. They utilized this data to develop novel immunotherapies for brain tumor patients.
Chief Financial Officer
Neil J. Laird is an experienced financial executive who works with emerging companies to provide accounting and finance-related services. Since 2017 he has worked with several technology and other companies as a consultant. Before that he was the Chief Financial Officer of Mobileum Inc., a private company providing roaming and other solutions to the telecommunications industry. Prior to this, he was Chief Financial Officer at SumTotal Systems, a provider of enterprise learning management systems and before that, Chief Financial Officer at
ADAC Laboratories, a provider of nuclear medicine and PET systems. Both were publicly traded companies. He also held senior management positions at Coherent Medical Lasers and Measurex Corporation. Mr. Laird has an MA from the University of Cambridge and qualified as a UK chartered accountant.
President, StemVax Therapeutics Inc.
Dr. Wheeler has over 30 years of immunology and neurology research experience. His leadership experience is highlighted by his position and previous roles at Cedar-Sinai Medical Center Department of Neurosurgery. Dr. Wheeler was a Professor in the Department for over 20 years, and also served as The Operations Director of Vaccine Manufacturing Laboratory (1997-2018), as part of the Precision Medicine Initiative for Brain Tumors (Department of Neurosurgery, Chair of the Institutional Animal Care and Use Committee (IACUC, 2006-2012), and Glioma Immunotherapy Core Director (2003-2018).
The research has been highlighted by publications in numerous high impact, paradigm shifting manuscripts and several patents. Dr. Wheeler has executed scientific aspects of commercialization, validation, funding, and marketing for the development of Alzheimer’s Disease (AD) biomarker technology.
Executive Board Member
John has spent the last three decades working with and investing in small-cap companies. John began his career on Wall Street as an Associate in the Equity Research Department of Smith Barney. He then joined Smith Barney’s parent company, the Travelers Corporation, as an analyst responsible for private and public investments in emerging businesses. John worked as a portfolio manager at several institutions, including Ingalls & Snyder, Lehman Brothers, and Barclays Capital, managing funds focused on small emerging growth companies.
John graduated from Fordham University with a bachelor’s degree in finance and a master’s degree in business administration from Columbia University.
Jason Anderson is experienced in the fields of biological discovery, genomic modeling, drug development, and national security.
From 2016-2020, he was a co-founder and member of the board of EdenRoc Sciences, LLC, a privately-held biotechnology company formed to cultivate world-class life sciences start-up companies to include Liberty BioSecurity, LLC, where he served as co-founder and Chief Executive Officer from 2014-2020. This integrated life sciences platform leveraged a dynamic intellectual property portfolio spanning pharmaceuticals, novel biology, genomics, and molecular diagnostics.
From 1998 to 2014, Mr. Anderson served as a diplomat for the United States Department of State. He has co-authored several granted patents in the life sciences and speaks on international affairs and biotechnology innovation. He is a graduate of the London School of Economics and Political Science and the University of California, San Diego and speaks Spanish and Chinese (Mandarin).
Renard has over 20 years’ experience as a Product Executive in Healthcare IT. He is currently the Senior Global Director for Infor Inc., 2013- current. Since 2001, he has served as COO and VP of Product management for leading healthcare IT companies, including KnowMed, Healthvision, and Quovadx. Renard leadership turns new ideas into profitable products through building successful cross-functional product development and management teams, fostering a culture of design-driven product development, microservices architecture and beautiful user experience. Renard has led the effort to
develop a multi-tenant interoperability solution with infused artificial intelligence powered by InforOS. He has also led sales, marketing, product management, product development, and service organizations of a cloud-based Healthcare Data Platform start-up company. More recently, Renard’s expertise has focused on software development for successful transition of on-premise products to Cloud. Renard’s Product development experience includes Health Interoperability, Digital Health, Health Analytics, and Artificial Intelligence.
Dr. King is a management consultant, administrator, researcher, external grant reviewer, and tenured professor with more than 15 years of administrative experience in for-profit, not-for-profit, federal agency, and academic environments. She obtained her doctoral and postdoctoral training at the University of Michigan, Harvard and the Coverdale Institute. Her past 5 years have been with the United States Department of Health and Human Services Food & Drug Administration (FDA/CDER & FDA/OEA) and National Institutes of Health Office of the NIH Director. Prior to these engagements, she was a senior administrator and Principal Investigator at Keystone Symposia on Molecular & Cellular Biology, Associate Academic Dean and Professor of Pharmaceutical Sciences in a college of pharmacy, and a tenured Professor of Management at an AACSB school of business.
Significant academic appointments include being a voting Member of the AMA/AAMC Liaison Committee on Medical Education (LCME), Commissioner at the North Central Association of Colleges & Schools, and Steering Committee Member of the CDC Health Disparities Institute Development Group. Her research, national presentations, and publications are in the areas of organizational behavior, advanced academic mentoring & positioning, graduate education training program implementation, and operational management. She has authored numerous peer-reviewed articles and book chapters and has edited a three-volume book series on managed care. Her consulting experience includes work with the Military District of Washington, Japan Consultant for the Department of Defense, American Council on Education, and multiple health care professional credentialing agencies.
Dr. Andrew Norris has a varied background in both business and the technology sector. He is Co-founder of The Midvale Group LLC in 2002, consulting in both the technology and biotechnology sector. Dr. Norris has also Co-founded BCN Biosciences in Pasadena, CA (2005), which is a privately held biotechnology company whose principal focus is in the area of oncology drug development. Dr. Norris has been directly responsible for, or co-raised over $20M in funding for the technology and Biotechnology sector. He currently serves as an officer/director at BCN Biosciences and also
holds a research faculty position at the University of California Los Angeles Department of Neuropsychiatry. Dr. Norris received his PhD from UCLA School of Medicine, Department of Molecular & Medical Pharmacology and Chemistry. His research focused on synthesizing molecular inhibitors against cancer cells. He also trained in the Surgical Oncology Department at UCLA focusing his research on novel drug discovery for breast cancer patients.
Dr. Lachlan Thompson Associate Professor Lachlan Thompson is a Principal Research Fellow at the Florey Institute for Neuroscience and Mental Health. He heads a research program dedicated to regenerative approaches to repair of the central nervous system, with a special focus on the use of pluripotent stem cells for functional reconstruction of circuitry affected in Parkinson’s disease, stroke and motor neuron disease. He has contributed more than 50 research papers on this topic in leading journals including the Journal of Neuroscience, Neurobiology of Disease, Proceedings of the National Academy of Science, Brain and Cell Reports. Dr. Thompson has is a partner investigator in the Australian government’s major Stem Cells initiative where
he sits on the committee for clinical translation and commercialization and plays an active role in contributing to policy-making on the regulation of experimental stem cell therapies. He also sits on the board of the Network for European CNS Transplantation and Repair and is president of the Asia-Pacific Association for Neural Transplantation and Repair. Dr. Thompson brings a wealth of experience in cutting-edge technology driving pre-clinical research in regenerative approaches to brain repair and also in understanding of the regulatory frameworks governing clinical translation and commercialization of stem cell therapies.
Revolutionary advances in the understanding of how our bodies can fight cancer, and how to put that information to use in treating existing tumors. NovAccess Global’s team of experts is working to strengthen the capability of the human body’s defense against cancer.
Stay up-to-date with our journey